Luis A. Mariscal-Ramírez, Josefina Alberú-Gómez, J. D. Amato-Martínez, Tommaso Bochicchio-Ricardelli, I. D. Campos-González, Victor R. Cervera-Saldaña, A. Chew-Wong, Alan Espinosa-Marrón, Mara Medeiro-Domingo, F. Molina-Segui, R. Muñoz-Arizpe, Hugo Laviada-Molina
Non-caloric sweeteners (NCS) are food additives with sweet taste used as a tool to substitute sugar consumption and reduce energy intake. There is scientific controversy surrounding possible risks of its use, which is under continuous discussion in
{"title":"Edulcorantes no calóricos y enfermedad renal: análisis de la evidencia","authors":"Luis A. Mariscal-Ramírez, Josefina Alberú-Gómez, J. D. Amato-Martínez, Tommaso Bochicchio-Ricardelli, I. D. Campos-González, Victor R. Cervera-Saldaña, A. Chew-Wong, Alan Espinosa-Marrón, Mara Medeiro-Domingo, F. Molina-Segui, R. Muñoz-Arizpe, Hugo Laviada-Molina","doi":"10.24875/nefro.19000100","DOIUrl":"https://doi.org/10.24875/nefro.19000100","url":null,"abstract":"Non-caloric sweeteners (NCS) are food additives with sweet taste used as a tool to substitute sugar consumption and reduce energy intake. There is scientific controversy surrounding possible risks of its use, which is under continuous discussion in","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87751585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-15DOI: 10.24875/NEFRO.M18000004
Deidra C. Crews, Aminu K. Bello, G. Saadi
Deidra C. Crews1,2,3*, Aminu K. Bello4 y Gamal Saadi5; World Kidney Day Steering Committee6** 1Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 2Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA; 3Johns Hopkins Center for Health Equity, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA; 4Division of Nephrology & Transplant Immunology, Department of Medicine, University of Alberta, Edmonton, Canada; 5Nephrology Unit, Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt
Deidra C. crews1,2,3 *， Aminu K. Bello4 y Gamal Saadi5;世界肾脏日指导委员会6** 1美国马里兰州巴尔的摩市约翰霍普金斯大学医学院医学系肾内科;2约翰霍普金斯医疗机构韦尔奇预防、流行病学和临床研究中心，美国马里兰州巴尔的摩;3约翰霍普金斯医疗机构约翰霍普金斯健康公平中心，美国马里兰州巴尔的摩;4加拿大埃德蒙顿阿尔伯塔大学医学系肾内科与移植免疫学研究室;5埃及吉萨开罗大学医学院内科肾内科
{"title":"Carga, acceso y disparidades en la enfermedad renal","authors":"Deidra C. Crews, Aminu K. Bello, G. Saadi","doi":"10.24875/NEFRO.M18000004","DOIUrl":"https://doi.org/10.24875/NEFRO.M18000004","url":null,"abstract":"Deidra C. Crews1,2,3*, Aminu K. Bello4 y Gamal Saadi5; World Kidney Day Steering Committee6** 1Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 2Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA; 3Johns Hopkins Center for Health Equity, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA; 4Division of Nephrology & Transplant Immunology, Department of Medicine, University of Alberta, Edmonton, Canada; 5Nephrology Unit, Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"122 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78170201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronic kidney disease (CKD) in Latin America is a huge public health problem requiring efforts from all the population sectors. Currently, the main challenges of the CKD attention in our region are: – Establish universal coverage of renal replacement therapies (RRT) for all patients requiring treatment. – Achieve a minimal RRT prevalence of 700 patients per million population in all countries. To get this goal, it is necessary to stimulate the use of cost-effective RRT: kidney transplant and peritoneal dialysis.
{"title":"La Sociedad Latinoamericana de Nefrología e Hipertensión y los retos de la enfermedad renal crónica en nuestra región","authors":"Alfonso M. Cueto-Manzano","doi":"10.24875/NEFRO.18000053","DOIUrl":"https://doi.org/10.24875/NEFRO.18000053","url":null,"abstract":"Chronic kidney disease (CKD) in Latin America is a huge public health problem requiring efforts from all the population sectors. Currently, the main challenges of the CKD attention in our region are: – Establish universal coverage of renal replacement therapies (RRT) for all patients requiring treatment. – Achieve a minimal RRT prevalence of 700 patients per million population in all countries. To get this goal, it is necessary to stimulate the use of cost-effective RRT: kidney transplant and peritoneal dialysis.","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72633713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guillermo Álvarez Estevez, Ramón García-Trabanino, Régulo Valdés-Miranda, J. Pérez-Oliva, J. E. Silva, Vicente Sánchez-Polo, G. Rodríguez, Nubia Cano, Néstor Ayala-Gómez, Claudio Mascheroni
Guillermo Álvarez-Estévez1, Ramón García-Trabanino2,3*, Régulo Valdés-Miranda4, Jorge Pérez-Oliva-Díaz5, Julio E. Silva6, Vicente Sánchez-Polo7,8, Gaspar Rodríguez9, Nubia Cano10,11, Néstor Ayala-Gómez12 y Claudio Mascheroni13,14 1Centro de Diagnóstico, Medicina avanzada, Conferencias Médicas y Telemedicina CEDIMAT, Santo Domingo, República Dominicana; 2Centro de Hemodiálisis, San Salvador, El Salvador; 3Fondo Social de Emergencia para la Salud, Cantón Tierra Blanca, Usulután, El Salvador; 4Caja de Seguro Social de Panamá, Panamá, Panamá; 5Instituto Nacional de Nefrología Dr. Abelardo Buch López, La Habana, Cuba; 6Medicina Corporativa de Diálisis, Guatemala, Guatemala; 7Servicio de Nefrología y Trasplante Renal, Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala; 8Programa de Formación de Nefrólogos, Universidad de San Carlos e Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala; 9Unidad de Hemodiálisis, Instituto Hondureño de Seguridad Social, Tegucigalpa, Honduras; 10Servicio de Nefrología, Hospital Escuela Antonio L. Fonseca, Managua, Nicaragua; 11Servicio de Hemodiálisis, Hospital Salud Integral, Managua, Nicaragua; 12Clínica de Hemodiálisis, San Salvador, El Salvador; 13Servicio de Nefrología San Pedro, San Pedro, Argentina; 14Universidad Nacional de Rosario, Rosario, Argentina EDITORIAL
Guillermo alvarez - estevez1, ramon garcia - trabanino2,3*， regulo valdes - miranda4, Jorge perez - oliva - diaz 5, Julio E. Silva6, Vicente sanchez - polo7,8, Gaspar rodriguez9, Nubia Cano10,11, nestor ayala - gomez 12和Claudio Mascheroni13,14 1诊断中心，高级医学，医学会议和远程医疗CEDIMAT，圣多明各，多米尼加共和国;2血液透析中心，萨尔瓦多圣萨尔瓦多;3紧急卫生社会基金，萨尔瓦多，usulutan, Tierra Blanca州;4巴拿马社会保障基金，巴拿马，巴拿马;5国家肾脏研究所Abelardo Buch博士lopez，古巴哈瓦那;6透析企业医学，危地马拉，危地马拉;7危地马拉社会保障研究所肾病和肾移植服务，危地马拉，危地马拉;8肾病学家培训方案，圣卡洛斯大学和危地马拉社会保障研究所，危地马拉，危地马拉;9洪都拉斯社会保障研究所血液透析股，洪都拉斯特古西加尔巴;10尼加拉瓜马那瓜Antonio L. Fonseca学校医院肾脏科;11血液透析服务，Salud Integral医院，尼加拉瓜马那瓜;12血液透析诊所，萨尔瓦多圣萨尔瓦多;13圣佩德罗肾脏服务，圣佩德罗，阿根廷;罗萨里奥国立大学，罗萨里奥，阿根廷
{"title":"Declaración de Panamá: contribuyendo a reducir la mortalidad en hemodiálisis en Centroamérica y el Caribe","authors":"Guillermo Álvarez Estevez, Ramón García-Trabanino, Régulo Valdés-Miranda, J. Pérez-Oliva, J. E. Silva, Vicente Sánchez-Polo, G. Rodríguez, Nubia Cano, Néstor Ayala-Gómez, Claudio Mascheroni","doi":"10.24875/NEFRO.18000049","DOIUrl":"https://doi.org/10.24875/NEFRO.18000049","url":null,"abstract":"Guillermo Álvarez-Estévez1, Ramón García-Trabanino2,3*, Régulo Valdés-Miranda4, Jorge Pérez-Oliva-Díaz5, Julio E. Silva6, Vicente Sánchez-Polo7,8, Gaspar Rodríguez9, Nubia Cano10,11, Néstor Ayala-Gómez12 y Claudio Mascheroni13,14 1Centro de Diagnóstico, Medicina avanzada, Conferencias Médicas y Telemedicina CEDIMAT, Santo Domingo, República Dominicana; 2Centro de Hemodiálisis, San Salvador, El Salvador; 3Fondo Social de Emergencia para la Salud, Cantón Tierra Blanca, Usulután, El Salvador; 4Caja de Seguro Social de Panamá, Panamá, Panamá; 5Instituto Nacional de Nefrología Dr. Abelardo Buch López, La Habana, Cuba; 6Medicina Corporativa de Diálisis, Guatemala, Guatemala; 7Servicio de Nefrología y Trasplante Renal, Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala; 8Programa de Formación de Nefrólogos, Universidad de San Carlos e Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala; 9Unidad de Hemodiálisis, Instituto Hondureño de Seguridad Social, Tegucigalpa, Honduras; 10Servicio de Nefrología, Hospital Escuela Antonio L. Fonseca, Managua, Nicaragua; 11Servicio de Hemodiálisis, Hospital Salud Integral, Managua, Nicaragua; 12Clínica de Hemodiálisis, San Salvador, El Salvador; 13Servicio de Nefrología San Pedro, San Pedro, Argentina; 14Universidad Nacional de Rosario, Rosario, Argentina EDITORIAL","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74845373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impacto de las condiciones de ingreso de pacientes a diálisis crónica sobre resultados clínicos y gasto sanitario durante el primer año de tratamiento","authors":"Santiago Torales, Juan Altuna, N. Jorgensen","doi":"10.24875/NEFRO.19000060","DOIUrl":"https://doi.org/10.24875/NEFRO.19000060","url":null,"abstract":"","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"185 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91476591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-30DOI: 10.24875/nefro.m18000003
Raúl G. Carlini, M. N. Campistrús, Liliana Andrade, Carlos R. del Blanco, L. Chifflet, Zulma Carolina Cruz de Trujillo, María E. Fernandes-Canziani, Thaïs A Forster, Marcus Gomes-Bastos, Gregorio T. Obrador, J. Pérez-Oliva, H. Poblete, Fernando Renjel-Claros
{"title":"Fe de errores: Recomendaciones para el estudio y tratamiento de la anemia en pacientes con enfermedad renal crónica: Actualización mayo 2017 [Nefrol Latinoam. 2017;14(3):85-116]","authors":"Raúl G. Carlini, M. N. Campistrús, Liliana Andrade, Carlos R. del Blanco, L. Chifflet, Zulma Carolina Cruz de Trujillo, María E. Fernandes-Canziani, Thaïs A Forster, Marcus Gomes-Bastos, Gregorio T. Obrador, J. Pérez-Oliva, H. Poblete, Fernando Renjel-Claros","doi":"10.24875/nefro.m18000003","DOIUrl":"https://doi.org/10.24875/nefro.m18000003","url":null,"abstract":"","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91145468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-30DOI: 10.24875/nefro.m18000001
G. B. Piccoli, Zhihong Liu, Adeera Levin
Chronic kidney disease affects approximately 10% of the world’s adult population: it is within the top 20 causes of death worldwide, and its impact on patients and their families can be devastating. World Kidney Day and International Women’s
{"title":"Enfermedad renal en la mujer: reflexiones en el Día Mundial del Riñón 2018","authors":"G. B. Piccoli, Zhihong Liu, Adeera Levin","doi":"10.24875/nefro.m18000001","DOIUrl":"https://doi.org/10.24875/nefro.m18000001","url":null,"abstract":"Chronic kidney disease affects approximately 10% of the world’s adult population: it is within the top 20 causes of death worldwide, and its impact on patients and their families can be devastating. World Kidney Day and International Women’s","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76471657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-30DOI: 10.24875/NEFRO.M18000002
Rolando Claure del Granado, Alejandra Pérez-Irigoyen
La Real Academia Española define la herbolaría como la botánica aplicada a la medicina. La medicina herbolaria se define como un producto derivado de una planta, el cual es utilizado con fines terapéuticos. Esta medicina incluye un gran número de sustancias extraídas de hierbas que van desde el té hecho en casa hasta productos que tienen que ser aprobados por organismos de regulación gubernamental1. En muchos lugares, basándose en el argumento de que «lo natural es lo más seguro», en las dos últimas décadas, y a pesar de brindarse suficiente atención a la garantía y control de calidad de estos medicamentos, su uso va en aumento y desafortunadamente, de la misma manera, el número de pacientes que han sufrido daños a la salud ocasionados por su consumo se ha incrementado2,3. En países con economías emergentes, hasta el 80% de su población depende de los sistemas de medicina herbolaria como su fuente primaria de salud. Por otro lado, en la Comunidad Europea, la medicina herbolaria representa una importante proporción del mercado farmacéutico4. En diferentes países de América Latina y el Caribe, la medicina tradicional representa una opción importante de respuesta ante las necesidades de atención a la salud4. En China, el 40% de la atención sanitara está a cargo de la medicina tradicional4. Entre el gran número de enfermedades crónicas tratadas con medicina herbolaria podemos encontrar las enfermedades renales. El efecto secundario de los medicamentos inmunosupresores, como los corticoesteroides empleados para el tratamiento de las enfermedades glomerulares, y la falta de acceso a estas opciones terapéuticas en muchos países, especialmente para las personas con ingresos económicos medio-bajos, ha llevado a muchos pacientes a la búsqueda de una alternativa terapéutica. Sin embargo, se sabe que muchas plantas medicinales causan nefrotoxicidad. Este efecto adverso de la medicina herbolaria, por lo general, no lo toma en cuenta la mayoría de los pacientes que la utilizan debido a la creencia errónea de que los medicamentos a base de hierbas son inocuos5.
{"title":"Formas especiales de injuria renal aguda (IRA) en Latinoamérica: IRA secundaria al uso de herbolaria","authors":"Rolando Claure del Granado, Alejandra Pérez-Irigoyen","doi":"10.24875/NEFRO.M18000002","DOIUrl":"https://doi.org/10.24875/NEFRO.M18000002","url":null,"abstract":"La Real Academia Española define la herbolaría como la botánica aplicada a la medicina. La medicina herbolaria se define como un producto derivado de una planta, el cual es utilizado con fines terapéuticos. Esta medicina incluye un gran número de sustancias extraídas de hierbas que van desde el té hecho en casa hasta productos que tienen que ser aprobados por organismos de regulación gubernamental1. En muchos lugares, basándose en el argumento de que «lo natural es lo más seguro», en las dos últimas décadas, y a pesar de brindarse suficiente atención a la garantía y control de calidad de estos medicamentos, su uso va en aumento y desafortunadamente, de la misma manera, el número de pacientes que han sufrido daños a la salud ocasionados por su consumo se ha incrementado2,3. En países con economías emergentes, hasta el 80% de su población depende de los sistemas de medicina herbolaria como su fuente primaria de salud. Por otro lado, en la Comunidad Europea, la medicina herbolaria representa una importante proporción del mercado farmacéutico4. En diferentes países de América Latina y el Caribe, la medicina tradicional representa una opción importante de respuesta ante las necesidades de atención a la salud4. En China, el 40% de la atención sanitara está a cargo de la medicina tradicional4. Entre el gran número de enfermedades crónicas tratadas con medicina herbolaria podemos encontrar las enfermedades renales. El efecto secundario de los medicamentos inmunosupresores, como los corticoesteroides empleados para el tratamiento de las enfermedades glomerulares, y la falta de acceso a estas opciones terapéuticas en muchos países, especialmente para las personas con ingresos económicos medio-bajos, ha llevado a muchos pacientes a la búsqueda de una alternativa terapéutica. Sin embargo, se sabe que muchas plantas medicinales causan nefrotoxicidad. Este efecto adverso de la medicina herbolaria, por lo general, no lo toma en cuenta la mayoría de los pacientes que la utilizan debido a la creencia errónea de que los medicamentos a base de hierbas son inocuos5.","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77841448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ramón García-Trabanino, L. Arroyo, Karen J. Courville, Carlos Ignacio Chica, Raúl Bohorques, G. Rodríguez, Justo Oyuela, Thyago Proença-de Moraes, H. Martínez, Guillermo Álvarez Estevez
Chronic kidney disease is a global issue and the prevalence of patients on renal replacement therapy (RRT) is constantly increasing. Many of our countries are of low/middle income and the common burden of diabetic and hypertensive patients is enhanced by the epidemic of Mesoamerican nephropathy. Considering this, the Central American and the Caribbean Association of Nephrology and Hypertension/Region 4 of the Latin American Society of Nephrology and Hypertension organized a series of meetings with the nephrology societies of Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, Dominican Republic and Cuba, to assess the situation and generate proposals. On this paper we present the results of the meeting of peritoneal dialysis (PD), its current status as option of dialytic RRT, and proposals to improve it. In 2017 the official population of the 8 countries was 69,283,417 inhabitants and 27,170 patients were on dialytic RRT: 18,020 (66.3%) on haemodialysis and 9,150 (33.7%) on PD, although with noteworthy differences between countries. Regional prevalence of patients in dialytic RRT: 392.2 patients pmp. By country: El Salvador 677.2, Panamá 526.3, Nicaragua 512.5, Guatemala 400.4, Dominican Republic 359.4, Honduras 345.1, Cuba 276.1, Costa Rica 138.9 pmp. Regional prevalence of PD patients: 132.1 pmp. El Salvador (380.1), Guatemala (217.2) and Costa Rica (103.1) have the highest prevalence; Dominican Republic (85.7), Honduras (20.1) and Cuba (6.1) the lowest. In Nicaragua and El Salvador most patients in the public health system still use obsolete PD modalities, indicating insufficient budgets or overloaded programs. Modern PD modalities are an effective RRT alternative not yet fully exploited in the region, and we present recommendations to enhance it.
{"title":"La diálisis peritoneal en Centroamérica y el Caribe: estado actual, necesidades y propuestas","authors":"Ramón García-Trabanino, L. Arroyo, Karen J. Courville, Carlos Ignacio Chica, Raúl Bohorques, G. Rodríguez, Justo Oyuela, Thyago Proença-de Moraes, H. Martínez, Guillermo Álvarez Estevez","doi":"10.24875/NEFRO.18000041","DOIUrl":"https://doi.org/10.24875/NEFRO.18000041","url":null,"abstract":"Chronic kidney disease is a global issue and the prevalence of patients on renal replacement therapy (RRT) is constantly increasing. Many of our countries are of low/middle income and the common burden of diabetic and hypertensive patients is enhanced by the epidemic of Mesoamerican nephropathy. Considering this, the Central American and the Caribbean Association of Nephrology and Hypertension/Region 4 of the Latin American Society of Nephrology and Hypertension organized a series of meetings with the nephrology societies of Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, Dominican Republic and Cuba, to assess the situation and generate proposals. On this paper we present the results of the meeting of peritoneal dialysis (PD), its current status as option of dialytic RRT, and proposals to improve it. In 2017 the official population of the 8 countries was 69,283,417 inhabitants and 27,170 patients were on dialytic RRT: 18,020 (66.3%) on haemodialysis and 9,150 (33.7%) on PD, although with noteworthy differences between countries. Regional prevalence of patients in dialytic RRT: 392.2 patients pmp. By country: El Salvador 677.2, Panamá 526.3, Nicaragua 512.5, Guatemala 400.4, Dominican Republic 359.4, Honduras 345.1, Cuba 276.1, Costa Rica 138.9 pmp. Regional prevalence of PD patients: 132.1 pmp. El Salvador (380.1), Guatemala (217.2) and Costa Rica (103.1) have the highest prevalence; Dominican Republic (85.7), Honduras (20.1) and Cuba (6.1) the lowest. In Nicaragua and El Salvador most patients in the public health system still use obsolete PD modalities, indicating insufficient budgets or overloaded programs. Modern PD modalities are an effective RRT alternative not yet fully exploited in the region, and we present recommendations to enhance it.","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"97 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76974294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Sanabria, M. Rosner, J. Vesga, A. Molano, Leyder Corzo, Patricia Rodríguez, C. Rios, A. Rivera, A. Bunch
Background: Remote monitoring technology that is specifically designed to be integrated into automated peritoneal dialysis (APD) systems gives both patients and their clinical team a powerful tool that can enhance communication, potentially improve adherence to the treatment, optimize fluid balance, and address potential complications of therapy in near real time. Objective: The objective of this study was to describe the implementation and early stages of an APD remote monitoring program as well as some early outcomes associated with this program. Methods: A cross-sectional study in incident and prevalent APD patients older than 18 years, who utilized remote monitoring and was enrolled to Renal Therapy Services Colombia network during the period from January 1 to December 31, 2017. For the analysis, we used descriptive statistics. Results: A program was implemented to provide training in the operation of both the device and the remote monitoring platform. Monitoring indicators were identified for the remote monitoring program to improve the safety and quality of the treatment; these indicators refer to characteristics of the APD prescription, adherence to the APD prescription, and blood pressure control. The adherence to APD treatment was 90.1%. Conclusions: A remote monitoring program for APD patients may be easily and efficiently implemented in health-care settings and may become a useful tool for the continuous improvement of the therapy through the development and monitoring of key clinical indicators.
{"title":"A remote management program in automated peritoneal dialysis patients in Colombia","authors":"M. Sanabria, M. Rosner, J. Vesga, A. Molano, Leyder Corzo, Patricia Rodríguez, C. Rios, A. Rivera, A. Bunch","doi":"10.24875/NEFRO.18000048","DOIUrl":"https://doi.org/10.24875/NEFRO.18000048","url":null,"abstract":"Background: Remote monitoring technology that is specifically designed to be integrated into automated peritoneal dialysis (APD) systems gives both patients and their clinical team a powerful tool that can enhance communication, potentially improve adherence to the treatment, optimize fluid balance, and address potential complications of therapy in near real time. Objective: The objective of this study was to describe the implementation and early stages of an APD remote monitoring program as well as some early outcomes associated with this program. Methods: A cross-sectional study in incident and prevalent APD patients older than 18 years, who utilized remote monitoring and was enrolled to Renal Therapy Services Colombia network during the period from January 1 to December 31, 2017. For the analysis, we used descriptive statistics. Results: A program was implemented to provide training in the operation of both the device and the remote monitoring platform. Monitoring indicators were identified for the remote monitoring program to improve the safety and quality of the treatment; these indicators refer to characteristics of the APD prescription, adherence to the APD prescription, and blood pressure control. The adherence to APD treatment was 90.1%. Conclusions: A remote monitoring program for APD patients may be easily and efficiently implemented in health-care settings and may become a useful tool for the continuous improvement of the therapy through the development and monitoring of key clinical indicators.","PeriodicalId":100947,"journal":{"name":"Nefrología Latinoamericana","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78946790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：